2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-180555
    SN38-(PEG)2-Pom-α
    SN38-(PEG)2-Pom-α is a selective PROTAC RPL15 degrader. SN38-(PEG)2-Pom-α induces ubiquitin-mediated degradation of RPL15 without affecting TOP1. SN38-(PEG)2-Pom-α induces damage-associated molecular pattern (DAMP) secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. SN38-(PEG)2-Pom-α enhances anti-PD-1 immunotherapy in a murine melanoma tumor model expressing human CRBN. SN38-(PEG)2-Pom-α can be used for melanoma research.
    SN38-(PEG)2-Pom-α
  • HY-180556
    PI3K/mTOR-IN-20
    PI3K/mTOR-IN-20 is a selective dual PI3K/mTOR inhibitor. PI3K/mTOR-IN-20 demonstrates nanomolar antiproliferative effects with IC50s of 0.380 and 0.090 μM for MRC-5 and Mlg2908 cells. PI3K/mTOR-IN-20 reduces Ashcroft scores, hydroxyproline content, collagen deposition, and downregulates fibrosis-related proteins, while restoring lung architecture in a Bleomycin-induced pulmonary fibrosis model. PI3K/mTOR-IN-20 shows a favorable safety profile with steady weight recovery and no distinct liver or kidney toxicity. PI3K/mTOR-IN-20 can be used for fetal lung fibroblasts research.
    PI3K/mTOR-IN-20
  • HY-180567
    PAC-Phe-Val 3088543-72-7
    PAC-Phe-Val is a potent HIV-1 protease inhibitor with an IC50 value of 33.10 nM. PAC-Phe-Val forms stable and strong interactions with critical active site residues, contributing to its high inhibitory potency. PAC-Phe-Val can be used for HIV/AIDS research.
    PAC-Phe-Val
  • HY-180579
    IRAK4-IN-33 2411497-72-6
    IRAK4-IN-33 (Compound 22) is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 0.36 nM. IRAK4-IN-33 can block the pro-inflammatory signaling pathway mediated by IRAK4 and inhibit the release of TNFα and IFNα. IRAK4-IN-33 shows weak inhibition for hERG channel (IC50 > 30 μM). IRAK4-IN-33 can be used for the research of inflammation and immunology, such as rheumatoid arthritis.
    IRAK4-IN-33
  • HY-180580
    SMU-C409 3113739-61-7 98%
    SMU-C409 is a TLR1/2 agonist with an EC50 of 65 nM in HEK-Blue hTLR2 Cells. SMU-C409 activates the TLR1/2–MyD88–NF-κB pathway, inducing TNF-α/IL-1β secretion and robust immune cell activation for antitumor immunomodulation. SMU-C409 shows low toxicity in virto. SMU-C409 can be used for cancer immunotherapy research.
    SMU-C409
  • HY-180582
    QND8 1778682-60-2
    QND8 is a selective and potent α7 nicotinic acetylcholine receptor (nAChR) agonist. QND8 can alleviate thermal hyperalgesia and mechanical hyperalgesia in carrageenan-induced inflammatory pain mouse model. QND8 can reduce the swelling of the mice feet, inhibit the release of pro-inflammatory factors at the inflammatory site, and prevent the infiltration of white blood cells. QND8 can be used for the research of inflammation and neurological disease, such as arthritis.
    QND8
  • HY-180608
    TCR-IN-1 2375042-31-0
    TCR-IN-1 (Compound A-33) is a TCR inhibitor. TCR-IN-1 blocks cytokine (IL-2, TNFα, IFNγ, IL-17A) release.
    TCR-IN-1
  • HY-180609
    TCR-IN-2 2375043-73-3 98%
    TCR-IN-2 (Compound A-68) is a TCR inhibitor. TCR-IN-2 inhibits the release of IFNγ and IL-2. TCR-IN-2 inhibits the time-dependent phosphorylation of CD3ζ. TCR-IN-2 inhibits TCR-mediated T cell activation, both in response to anti-CD3 antibodies and in response to human cells with unmatched HLA.
    TCR-IN-2
  • HY-18060B
    Bradanicline tosylate 1111942-11-0 98%
    Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline tosylate exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline tosylate possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline tosylate requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline tosylate is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough.
    Bradanicline tosylate
  • HY-180617
    5-HT2CR allosteric modulator 1 2376501-96-9
    5-HT2CR modulator 1 (Compound 3B) is a selective, positive ago-allosteric modulator of 5HT2CR with an EC50 of 8 nM. 5-HT2CR modulator 1 is also a selective 5HT2CR agonist with an EC50 of 25 nM. 5-HT2CR modulator 1 reduces food intake.
    5-HT2CR allosteric modulator 1
  • HY-180633
    (2R,5S)-2,5-Diaminohexanoate 1821798-97-3
    (2R,5S)-2,5-Diaminohexanoate is an endogenous metabolite.
    (2R,5S)-2,5-Diaminohexanoate
  • HY-180652
    c-Kit-IN-13 3041025-10-6 98%
    c-Kit-IN-13 (Compound I) is a c-kit kinase inhibitor. c-Kit-IN-13 inhibits the autophosphorylation of wild-type c-kit, with an IC50 of 0.3 nM for pKIT. c-Kit-IN-13 inhibits Exon 11 KIT, with an IC50 of 0.9 nM. c-Kit-IN-13 can be used in the research of mast cell-mediated diseases such as urticaria.
    c-Kit-IN-13
  • HY-180653
    c-Kit-IN-14 3041025-49-1
    c-Kit-IN-14 (Compound 1) is a c-kit kinase inhibitor. c-Kit-IN-14 inhibits the phosphorylation of wild-type c-kit, with an IC50 of 0.4 nM for pKIT. c-Kit-IN-14 inhibits Exon 11 KIT, with an IC50 of 0.4 nM. c-Kit-IN-14 can be used in the research of mast cell-mediated diseases such as urticaria.
    c-Kit-IN-14
  • HY-180674
    LA24
    LA24 is a potent STING allosteric agonist, with an EC₅₀ of 0.82 μM. LA24 induces the phosphorylation of STING and IRF3. LA24 can be used for the study of STING-targeted immunotherapies.
    LA24
  • HY-180781
    ADAMTS-5-IN-4
    ADAMTS-5-IN-4 (Compound 4b) is a selective ADAMTS5 inhibitor with an IC₅₀ of 9.4 μM. ADAMTS-5-IN-4 significantly inhibits the degradation of Aggrecan in the implants of the osteoarthritis model. ADAMTS-5-IN-4 effectively inhibits the pseudopod elongation and directional migration of ovarian cancer cells. ADAMTS-5-IN-4 shows significant cytotoxicity to HEK293T cells, human chondrocytes, and porcine chondrocyte implants. ADAMTS-5-IN-4 can be used for the study of osteoarthritis and ovarian cancer.
    ADAMTS-5-IN-4
  • HY-180792
    CK-571 1119536-89-8
    CK-571 is a potent and selective inhibitor of smooth muscle myosin-2 (SMM), with an IC50 value of 86 nM. CK-571 exhibits IC50 values for cardiac muscle myosin (CMM), skeletal muscle myosin (SKM), and non-muscle myosin-2A (NMM-2A) of 2.3, 42, and 0.58 μM, respectively. CK-571 can be used for research on asthma, chronic obstructive pulmonary disease, and other smooth muscle-related diseases.
    CK-571
  • HY-180799
    Cathepsin L-IN-6 3077842-39-5
    Cathepsin L-IN-6 (Compound 6a) is a selective cathepsin L inhibitor with an IC50 of 0.021 μM. Cathepsin L-IN-6 suppresses cathepsin L activity by directly binding to cathepsin L. Cathepsin L-IN-6 inhibits IL-6 and IL-8. Cathepsin L-IN-6 shows a high anti-inflammatory activity. Cathepsin L-IN-6 can be used in the research of acute lung injury.
    Cathepsin L-IN-6
  • HY-180800
    Anti-inflammatory agent 110
    Anti-inflammatory agent 110 (Compound 7b) is a analgesic/anti-inflammatory agent. Anti-inflammatory agent 110 has a good binding affinity for COX-2. Anti-inflammatory agent 110 demonstrated potent analgesic and anti-inflammatory activities in the mouse hot plate test and the rat carrageenan edema model.
    Anti-inflammatory agent 110
  • HY-180803
    LH17 98%
    LH17, a Kaempferol (HY-14590) derivative, is a potent and selective PDE4 inhibitor (PDE4D2 IC50 = 73 nM, PDE4B2 IC50 = 190 nM). LH17 exhibits remarkable selectivity (>136-fold) against other PDE isoforms (PDE1B/2A/3A/5A/8A/9A/10A) (IC50 > 10000 nM), with the exception of PDE7A1 (IC50 = 300 nM). LH17 distinctly interacts with PDE4 M-pocket. LH17 demonstrates remarkable anti-fibrotic efficacy in both in vitro and in vivo models. LH17 can be used for idiopathic pulmonary fibrosis (IPF) research.
    LH17
  • HY-180813
    RORγ-IN-3
    RORγ-IN-3 (Compound 21) is a potent and highly selective RORγ inhibitor with an EC50 of 84 nM. RORγ-IN-3 can effectively inhibit the production of IL-17, with an IC₅₀ value of 1.0 μM. RORγ-IN-3 can be used for the study of autoimmune diseases.
    RORγ-IN-3
Cat. No. Product Name / Synonyms Application Reactivity